Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
35
BDULF Quote, Financials, Valuation and Earnings
Last price:
$0.61
Seasonality move
:
4.53%
Day range:
$0.61 - $0.61
52-week range:
$0.56 - $0.85
Dividend yield:
3.74%
P/E ratio:
74.69x
P/S ratio:
3.11x
P/B ratio:
3.12x
Volume:
2K
Avg. volume:
3K
1-year change:
-28.92%
Market cap:
$9.6B
Revenue:
$3.1B
EPS (TTM):
$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDULF
Bangkok Dusit Medical Services Public Co. Ltd.
|
-- | -- | -- | -- | -- |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
BUHPF
Bumrungrad Hospital Public Co., Ltd.
|
-- | -- | -- | -- | -- |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$383K | -$0.02 | -24.9% | -15.25% | $3.88 |
|
NIVF
NewGenIVF Group Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDULF
Bangkok Dusit Medical Services Public Co. Ltd.
|
$0.61 | -- | $9.6B | 74.69x | $0.01 | 3.74% | 3.11x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
BUHPF
Bumrungrad Hospital Public Co., Ltd.
|
$5.35 | -- | $4.3B | 90.83x | $0.06 | 2.8% | 5.70x |
|
CVM
CEL-SCI Corp.
|
$4.91 | $42.50 | $14.9M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.88 | $27.9M | -- | $0.00 | 0% | 22.51x |
|
NIVF
NewGenIVF Group Ltd.
|
$0.90 | -- | $1.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDULF
Bangkok Dusit Medical Services Public Co. Ltd.
|
7.11% | -0.653 | 2.09% | 1.12x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
BUHPF
Bumrungrad Hospital Public Co., Ltd.
|
0.08% | 0.217 | 0.02% | 4.40x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
NIVF
NewGenIVF Group Ltd.
|
-- | 0.341 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDULF
Bangkok Dusit Medical Services Public Co. Ltd.
|
-- | $165.3M | 14.38% | 15.71% | 20.2% | $129.4M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
BUHPF
Bumrungrad Hospital Public Co., Ltd.
|
-- | $68.7M | 26.98% | 27.01% | 38.69% | $36.6M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
NIVF
NewGenIVF Group Ltd.
|
-- | -- | -- | -- | -- | -- |
Bangkok Dusit Medical Services Public Co. Ltd. vs. Competitors
-
Which has Higher Returns BDULF or AIM?
AIM ImmunoTech has a net margin of 15.48% compared to Bangkok Dusit Medical Services Public Co. Ltd.'s net margin of -10571.43%. Bangkok Dusit Medical Services Public Co. Ltd.'s return on equity of 15.71% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital BDULFBangkok Dusit Medical Services Public Co. Ltd.37.03% -- $3.4B AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About BDULF or AIM?
Bangkok Dusit Medical Services Public Co. Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Bangkok Dusit Medical Services Public Co. Ltd., analysts believe AIM ImmunoTech is more attractive than Bangkok Dusit Medical Services Public Co. Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BDULFBangkok Dusit Medical Services Public Co. Ltd.0 0 0 AIMAIM ImmunoTech1 0 0 -
Is BDULF or AIM More Risky?
Bangkok Dusit Medical Services Public Co. Ltd. has a beta of -0.025, which suggesting that the stock is 102.513% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock BDULF or AIM?
Bangkok Dusit Medical Services Public Co. Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 3.74%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services Public Co. Ltd. pays 74.55% of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services Public Co. Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDULF or AIM?
Bangkok Dusit Medical Services Public Co. Ltd. quarterly revenues are $826.7M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Bangkok Dusit Medical Services Public Co. Ltd.'s net income of $127.9M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Bangkok Dusit Medical Services Public Co. Ltd.'s price-to-earnings ratio is 74.69x while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services Public Co. Ltd. is 3.11x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDULFBangkok Dusit Medical Services Public Co. Ltd.3.11x 74.69x $826.7M $127.9M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns BDULF or BUHPF?
Bumrungrad Hospital Public Co., Ltd. has a net margin of 15.48% compared to Bangkok Dusit Medical Services Public Co. Ltd.'s net margin of 30.84%. Bangkok Dusit Medical Services Public Co. Ltd.'s return on equity of 15.71% beat Bumrungrad Hospital Public Co., Ltd.'s return on equity of 27.01%.
Company Gross Margin Earnings Per Share Invested Capital BDULFBangkok Dusit Medical Services Public Co. Ltd.37.03% -- $3.4B BUHPFBumrungrad Hospital Public Co., Ltd.52.46% -- $887.3M -
What do Analysts Say About BDULF or BUHPF?
Bangkok Dusit Medical Services Public Co. Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Bumrungrad Hospital Public Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Bangkok Dusit Medical Services Public Co. Ltd. has higher upside potential than Bumrungrad Hospital Public Co., Ltd., analysts believe Bangkok Dusit Medical Services Public Co. Ltd. is more attractive than Bumrungrad Hospital Public Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BDULFBangkok Dusit Medical Services Public Co. Ltd.0 0 0 BUHPFBumrungrad Hospital Public Co., Ltd.0 0 0 -
Is BDULF or BUHPF More Risky?
Bangkok Dusit Medical Services Public Co. Ltd. has a beta of -0.025, which suggesting that the stock is 102.513% less volatile than S&P 500. In comparison Bumrungrad Hospital Public Co., Ltd. has a beta of -0.048, suggesting its less volatile than the S&P 500 by 104.845%.
-
Which is a Better Dividend Stock BDULF or BUHPF?
Bangkok Dusit Medical Services Public Co. Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 3.74%. Bumrungrad Hospital Public Co., Ltd. offers a yield of 2.8% to investors and pays a quarterly dividend of $0.06 per share. Bangkok Dusit Medical Services Public Co. Ltd. pays 74.55% of its earnings as a dividend. Bumrungrad Hospital Public Co., Ltd. pays out 51.12% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDULF or BUHPF?
Bangkok Dusit Medical Services Public Co. Ltd. quarterly revenues are $826.7M, which are larger than Bumrungrad Hospital Public Co., Ltd. quarterly revenues of $181.9M. Bangkok Dusit Medical Services Public Co. Ltd.'s net income of $127.9M is higher than Bumrungrad Hospital Public Co., Ltd.'s net income of $56.1M. Notably, Bangkok Dusit Medical Services Public Co. Ltd.'s price-to-earnings ratio is 74.69x while Bumrungrad Hospital Public Co., Ltd.'s PE ratio is 90.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services Public Co. Ltd. is 3.11x versus 5.70x for Bumrungrad Hospital Public Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDULFBangkok Dusit Medical Services Public Co. Ltd.3.11x 74.69x $826.7M $127.9M BUHPFBumrungrad Hospital Public Co., Ltd.5.70x 90.83x $181.9M $56.1M
-
Which has Higher Returns BDULF or CVM?
CEL-SCI Corp. has a net margin of 15.48% compared to Bangkok Dusit Medical Services Public Co. Ltd.'s net margin of --. Bangkok Dusit Medical Services Public Co. Ltd.'s return on equity of 15.71% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital BDULFBangkok Dusit Medical Services Public Co. Ltd.37.03% -- $3.4B CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About BDULF or CVM?
Bangkok Dusit Medical Services Public Co. Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that CEL-SCI Corp. has higher upside potential than Bangkok Dusit Medical Services Public Co. Ltd., analysts believe CEL-SCI Corp. is more attractive than Bangkok Dusit Medical Services Public Co. Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BDULFBangkok Dusit Medical Services Public Co. Ltd.0 0 0 CVMCEL-SCI Corp.1 0 0 -
Is BDULF or CVM More Risky?
Bangkok Dusit Medical Services Public Co. Ltd. has a beta of -0.025, which suggesting that the stock is 102.513% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock BDULF or CVM?
Bangkok Dusit Medical Services Public Co. Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 3.74%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services Public Co. Ltd. pays 74.55% of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services Public Co. Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDULF or CVM?
Bangkok Dusit Medical Services Public Co. Ltd. quarterly revenues are $826.7M, which are larger than CEL-SCI Corp. quarterly revenues of --. Bangkok Dusit Medical Services Public Co. Ltd.'s net income of $127.9M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Bangkok Dusit Medical Services Public Co. Ltd.'s price-to-earnings ratio is 74.69x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services Public Co. Ltd. is 3.11x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDULFBangkok Dusit Medical Services Public Co. Ltd.3.11x 74.69x $826.7M $127.9M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns BDULF or IGC?
IGC Pharma, Inc. has a net margin of 15.48% compared to Bangkok Dusit Medical Services Public Co. Ltd.'s net margin of -953.4%. Bangkok Dusit Medical Services Public Co. Ltd.'s return on equity of 15.71% beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital BDULFBangkok Dusit Medical Services Public Co. Ltd.37.03% -- $3.4B IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About BDULF or IGC?
Bangkok Dusit Medical Services Public Co. Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that IGC Pharma, Inc. has higher upside potential than Bangkok Dusit Medical Services Public Co. Ltd., analysts believe IGC Pharma, Inc. is more attractive than Bangkok Dusit Medical Services Public Co. Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BDULFBangkok Dusit Medical Services Public Co. Ltd.0 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is BDULF or IGC More Risky?
Bangkok Dusit Medical Services Public Co. Ltd. has a beta of -0.025, which suggesting that the stock is 102.513% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock BDULF or IGC?
Bangkok Dusit Medical Services Public Co. Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 3.74%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services Public Co. Ltd. pays 74.55% of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services Public Co. Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDULF or IGC?
Bangkok Dusit Medical Services Public Co. Ltd. quarterly revenues are $826.7M, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Bangkok Dusit Medical Services Public Co. Ltd.'s net income of $127.9M is higher than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Bangkok Dusit Medical Services Public Co. Ltd.'s price-to-earnings ratio is 74.69x while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services Public Co. Ltd. is 3.11x versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDULFBangkok Dusit Medical Services Public Co. Ltd.3.11x 74.69x $826.7M $127.9M IGCIGC Pharma, Inc.22.51x -- $191K -$1.8M
-
Which has Higher Returns BDULF or NIVF?
NewGenIVF Group Ltd. has a net margin of 15.48% compared to Bangkok Dusit Medical Services Public Co. Ltd.'s net margin of --. Bangkok Dusit Medical Services Public Co. Ltd.'s return on equity of 15.71% beat NewGenIVF Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDULFBangkok Dusit Medical Services Public Co. Ltd.37.03% -- $3.4B NIVFNewGenIVF Group Ltd.-- -- -- -
What do Analysts Say About BDULF or NIVF?
Bangkok Dusit Medical Services Public Co. Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand NewGenIVF Group Ltd. has an analysts' consensus of -- which suggests that it could grow by 8253.75%. Given that NewGenIVF Group Ltd. has higher upside potential than Bangkok Dusit Medical Services Public Co. Ltd., analysts believe NewGenIVF Group Ltd. is more attractive than Bangkok Dusit Medical Services Public Co. Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BDULFBangkok Dusit Medical Services Public Co. Ltd.0 0 0 NIVFNewGenIVF Group Ltd.0 0 0 -
Is BDULF or NIVF More Risky?
Bangkok Dusit Medical Services Public Co. Ltd. has a beta of -0.025, which suggesting that the stock is 102.513% less volatile than S&P 500. In comparison NewGenIVF Group Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BDULF or NIVF?
Bangkok Dusit Medical Services Public Co. Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 3.74%. NewGenIVF Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services Public Co. Ltd. pays 74.55% of its earnings as a dividend. NewGenIVF Group Ltd. pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services Public Co. Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDULF or NIVF?
Bangkok Dusit Medical Services Public Co. Ltd. quarterly revenues are $826.7M, which are larger than NewGenIVF Group Ltd. quarterly revenues of --. Bangkok Dusit Medical Services Public Co. Ltd.'s net income of $127.9M is higher than NewGenIVF Group Ltd.'s net income of --. Notably, Bangkok Dusit Medical Services Public Co. Ltd.'s price-to-earnings ratio is 74.69x while NewGenIVF Group Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services Public Co. Ltd. is 3.11x versus -- for NewGenIVF Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDULFBangkok Dusit Medical Services Public Co. Ltd.3.11x 74.69x $826.7M $127.9M NIVFNewGenIVF Group Ltd.-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
